Peters R W, Gold M R
Department of Medicine, Division of Cardiology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Med Clin North Am. 2001 Mar;85(2):343-67, xi. doi: 10.1016/s0025-7125(05)70319-9.
The implantable cardioverter defibrillator (ICD) represents an important development in the effort to reduce the incidence of sudden cardiac death (almost 400,000 yearly in the United States). Early generation ICDs, which required epicardial lead systems and abdominal placement of the pulse generator, have been replaced by transvenous leads and pectoral implants. Other important refinements, which include biphasic waveforms, extensive memory capability, antitachycardia pacing, and enhanced sensing algorithms, have greatly improved patient tolerance. Ongoing trials and those in the planning stages will continue to expand the indications for ICDs and will focus on cost-effectiveness.
植入式心脏复律除颤器(ICD)是降低心脏性猝死发生率(在美国每年近40万例)努力中的一项重要进展。早期一代的ICD需要心外膜导联系统且脉冲发生器置于腹部,现已被经静脉导联和胸壁植入所取代。其他重要改进,包括双相波形、大容量存储功能、抗心动过速起搏以及增强的感知算法,极大地提高了患者耐受性。正在进行的试验以及处于规划阶段的试验将继续扩大ICD的适应证,并将聚焦于成本效益。